{"entity":{"type":"insider","cik":"0001441461","url":"/insider/0001441461","json_url":"/insider/0001441461.json","name":"Glickman Mark A","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":5,"n_filings":4,"first":"2014-11-24","last":"2022-12-09","span_basis":"filed_date"},"name_variants":[{"name":"Glickman Mark A","source":"filing","n_filings":4,"first_seen":"2014-11-24","last_seen":"2022-12-09"}],"transactions":[{"id":6927267,"accession":"0001209191-22-060586","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-060586","line_url":"/filing/0001209191-22-060586#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001441461","owner_name":"Glickman Mark A","owner_display_name":"Glickman Mark A","owner_url":"/insider/0001441461","role":"Officer (Co-Chief Executive Officer)","role_mark":"O","role_mark_label":"Officer (Co-Chief Executive Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":440.0,"shares_display":"440","price_per_share":4.9215,"price_display":"4.92","price_state":"stated","total_value":2165.46,"total_display":"2,165.46","total_whole":"2,165","shares_owned_after":1294.0,"shares_owned_after_display":"1,294","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-06","filed_date":"2022-12-09","scope":"insider"},{"id":6116671,"accession":"0001104659-18-019362","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-18-019362","line_url":"/filing/0001104659-18-019362#line-1","is_derivative":false,"issuer_cik":"0001441461","issuer_name":"Aralez Pharmaceuticals Inc.","issuer_ticker":"ARLZ","issuer_name_source":null,"issuer_url":"/issuer/0001441461","owner_cik":"0001441461","owner_name":"Glickman Mark A","owner_display_name":"Glickman Mark A","owner_url":"/insider/0001441461","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Shares, without par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5725.0,"shares_display":"5,725","price_per_share":1.7,"price_display":"1.70","price_state":"stated","total_value":9732.5,"total_display":"9,732.50","total_whole":"9,733","shares_owned_after":250188.0,"shares_owned_after_display":"250,188","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-19","filed_date":"2018-03-21","scope":"insider"},{"id":2208301,"accession":"0001104659-16-121881","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-16-121881","line_url":"/filing/0001104659-16-121881#line-1","is_derivative":false,"issuer_cik":"0001441461","issuer_name":"Aralez Pharmaceuticals Inc.","issuer_ticker":"ARLZ","issuer_name_source":null,"issuer_url":"/issuer/0001441461","owner_cik":"0001441461","owner_name":"Glickman Mark A","owner_display_name":"Glickman Mark A","owner_url":"/insider/0001441461","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Shares, without par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":3.682,"price_display":"3.68","price_state":"stated","total_value":92050.0,"total_display":"92,050.00","total_whole":"92,050","shares_owned_after":186553.0,"shares_owned_after_display":"186,553","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-16","filed_date":"2016-05-18","scope":"insider"},{"id":6236976,"accession":"0001209191-14-070830","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-14-070830","line_url":"/filing/0001209191-14-070830","is_derivative":false,"issuer_cik":"0001182129","issuer_name":"AUXILIUM PHARMACEUTICALS INC","issuer_ticker":"AUXL","issuer_name_source":null,"issuer_url":"/issuer/0001182129","owner_cik":"0001441461","owner_name":"Glickman Mark A","owner_display_name":"Glickman Mark A","owner_url":"/insider/0001441461","role":"Officer (EVP - Sales and Marketing)","role_mark":"O","role_mark_label":"Officer (EVP - Sales and Marketing)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP - Sales and Marketing","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":47952.0,"shares_display":"47,952","price_per_share":33.16514337671004,"price_display":"33.17","price_state":"stated","total_value":1590334.9552,"total_display":"1,590,334.96","total_whole":"1,590,335","shares_owned_after":27911.0,"shares_owned_after_display":"27,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-11-20","filed_date":"2014-11-24","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":5,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":4,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":5},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000025743","name":"TherapeuticsMD, Inc.","url":"/issuer/0000025743","role":"Officer (Co-Chief Executive Officer)","n_filings":1,"first_seen":"2022-12-09","last_seen":"2022-12-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001660719","name":"Aralez Pharmaceuticals Inc.","url":"/issuer/0001660719","role":"Officer (Chief Commercial Officer)","n_filings":2,"first_seen":"2016-05-18","last_seen":"2018-03-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001182129","name":"AUXILIUM PHARMACEUTICALS INC","url":"/issuer/0001182129","role":"Officer (EVP - Sales and Marketing)","n_filings":1,"first_seen":"2014-11-24","last_seen":"2014-11-24"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001441461","retrieved_at":"2026-08-26T19:42:02+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}